Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.
about
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individualsPathogenesis of human immunodeficiency virus infectionAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Broadly Neutralizing Antibodies for HIV EradicationImmunity to retroviral infection: the Friend virus modelPassive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Human retroviruses in leukaemia and AIDS: reflections on their discovery, biology and epidemiology.Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasmaPharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Pediatric human immunodeficiency virus infection.Intravenous immunoglobulin in HIV infection: evidence for the efficacy of treatment.Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.Antiviral therapy: current concepts and practicesCombined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.Clinical experience with therapeutic AIDS vaccines.Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120HIV infection in healthcare workers. How great is the risk? What can be done before and after exposure?AIDS and the lung. 2--Antiretroviral treatment in human immunodeficiency virus disease.Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.Passive antibody protection of cats against feline immunodeficiency virus infection.Passive immunity in the prevention of maternal-fetal transmission of human immunodeficiency virus infection.Immunotherapy for infectious diseases.Postconditioning hormesis put in perspective: an overview of experimental and clinical studies.Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti-HIV antibodies in vitro.Pitfalls in HIV testing.Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement
P2860
Q24560010-5D86D972-E699-463F-B6AC-E5CA2CA819C2Q24634681-82C41EDB-0968-479A-91D6-CA8381845039Q27469855-2D508863-2C1A-4887-9AED-12399DE2FE17Q28073939-E75C0298-5830-47E4-8FA0-1ED05A669176Q28243606-4C288A66-30F3-488F-AAB1-E2A39D908667Q33778686-489F186B-BA1A-4B6A-9E40-24F14DE9320DQ33822379-BA96DF3A-0665-4B7A-9EC2-41FAB9590E71Q33880904-2BC41243-EDAC-4CF9-B7C9-27B1A7F115DFQ34097650-863EAEB5-4A58-4CAB-9FFE-192830FDECF7Q34389695-96B2B27B-2C6A-4C78-92BD-7D146C02ACBFQ34702647-D1997158-395E-498F-A096-605C6B24B860Q35137276-96AFB5CC-BFD2-489B-8507-A5439B0A7CD9Q35325810-9D3AD802-7EF3-48CD-8422-89A8463EF03EQ35372072-B6A3528C-2324-4C73-8559-14E7D4082F51Q35625556-51CD737F-2C88-4B75-9A59-A9E9E81C68CFQ35894716-9A1B6DB0-4707-44EE-959F-DD7E93480D7CQ36070394-3392C457-7505-4025-92A2-2A9688EE962DQ36106061-B67F2A17-FB70-4590-BFAC-6CB964551E7DQ36198648-D7D9DBC8-0D37-4C97-93F5-2D2B86345E7BQ36690500-22E6B6B3-82FB-4CA7-B65B-BFA26A2EF6FAQ37640048-9D7721EA-AA73-48F9-8BA4-92DC63D3234DQ38310881-2FB947F0-C558-4370-ABCE-A34AA8CD20AEQ38643834-6871FECD-F4D0-4DF0-B907-C4C605458D85Q40062003-1CD452D3-5EF5-4AAA-8230-6EAA84113E09Q40643799-4D401D6F-0E36-4A1E-B946-B14835700DB7Q41168545-68055286-2FF2-49A5-9A03-87B26CB84672Q42764966-71AE0A0E-6157-4FDD-B512-DE7BE62C9DD2Q45845087-51B1CCF2-8186-499E-9208-F4A8043E8AD2Q49967105-7AE66271-1BD3-48AA-9971-1DECAFB0518AQ58292725-518E1258-DC6D-4ECF-A94E-D4786F0CA43E
P2860
Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Passive immunoneutralization o ...... n patients with advanced AIDS.
@en
Passive immunoneutralization o ...... n patients with advanced AIDS.
@nl
type
label
Passive immunoneutralization o ...... n patients with advanced AIDS.
@en
Passive immunoneutralization o ...... n patients with advanced AIDS.
@nl
prefLabel
Passive immunoneutralization o ...... n patients with advanced AIDS.
@en
Passive immunoneutralization o ...... n patients with advanced AIDS.
@nl
P2093
P1433
P1476
Passive immunoneutralization o ...... n patients with advanced AIDS.
@en
P2093
G G Jackson
J C Despotes
J T Perkins
P304
P356
10.1016/S0140-6736(88)90468-0
P407
P577
1988-09-01T00:00:00Z